Published in final edited form as:

Clin Investig (Lond). 2011 April ; 1(4): 546–555. doi:10.4155/cli.11.26.

Personalized therapy for urothelial cancer: review of the clinical evidence

Elizabeth A. Guancial, M. D.,

Clinical Fellow in Hematology and Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Smith 353, Boston, MA 02115, 617-632-3779 (telephone), 617-632-5822 (fax),
eguancial@partners.org

Dipanjan Chowdhury, Ph.D., and

Assistant Professor, Dana Farber Cancer Institute, 450 Brookline Avenue, Jimmy Fund 5-517, Boston, MA 02115, 617-582-8639 (telephone), 617-582-8213 (fax),
Dipanjan_Chowdhury@DFCI.HARVARD.EDU

Jonathan E. Rosenberg, M.D.

Assistant Professor, Dana Farber Cancer Institute, 450 Brookline Avenue, Dana 1230, Boston, MA 02115, 617-632-4524 (telephone), 617-632-2165 (fax),
Jonathan_Rosenberg@DFCI.HARVARD.EDU

Abstract

Despite a detailed understanding of the molecular aberrations driving the development of urothelial cancers, this knowledge has not translated into advances for the treatment of this disease. Urothelial cancers are chemosensitive, and platinum-based combination chemotherapy remains the standard of care for advanced disease, as well as neoadjuvant and adjuvant therapy for locally advanced disease. However, nearly half of patients who undergo resection of locally advanced urothelial cancer will relapse and eventually develop platinum-resistant disease. Clinical trials of targeted agents against angiogenesis and growth factors, as well as novel chemotherapeutics, have generally been unsuccessful in urothelial cancers. Improvements in the therapeutic arsenal for urothelial cancer depend upon identification of new targets and strategies to overcome platinum resistance.

Introduction

The era of personalized medicine has already revolutionized the approach to a number of malignancies. For example, in breast cancer, from determining the benefit of adjuvant chemotherapy to selecting treatment for HER2 positive disease, molecular diagnostics has enabled oncologists to tailor therapy to an individual patient's cancer beyond clinicopathologic characteristics such as stage and histologic grade [1,2]. Ground-breaking work has emerged in the treatment of melanoma [3] and non-small cell lung cancer [4] that has the potential to transform fatal malignancies into treatable conditions. The hope is that this same possibility exists for urothelial cancers for which the only treatment options remain standard chemotherapy and for whom the majority of patients derive limited benefit.

While our understanding of the molecular changes in urothelial cancers has rapidly evolved over the last few decades, our therapeutic arsenal has not. First-line treatment for advanced disease remains platinum-based combination chemotherapy, and no FDA-approved second-line treatment exists. Attempts to improve current therapies have focused on dose intensity and combination doublet and triplet regimens without substantial gains, and unlike in other malignancies, targeted therapies have failed thus far to advance the standard of care beyond cytotoxic chemotherapy. Furthermore, it is unclear whether the multiple biomarkers which

have been identified are responsible for the aggressive phenotype or rather, are secondary to other driving mechanisms. Significant efforts to address these unmet needs are underway and range from identification of new molecular targets to testing of novel chemotherapeutic agents and targeted therapies to elucidating the mechanisms of cisplatin resistance.

Diagnosis and treatment of urothelial carcinomas

An estimated 70,500 new cases and 14,500 deaths in 2010, will be attributed to bladder cancer in the United States alone, making it the fourth most common cancer and ninth leading cause of cancer-related deaths among men [5]. In addition to the human cost, multiple economic analyses demonstrate that bladder cancer is among the most expensive to treat due to the invasive nature of surveillance and treatment with one group predicting a lifetime cost between \$99,000 and \$120,000 [6]. Bladder cancer is three times more common in men than women. The majority of patients are elderly, with a median age at presentation in men and women of 72 and 74 years, respectively [7]. Tobacco use is the strongest risk factor for development of urothelial cancer; other risk factors include occupational exposures to aniline dyes and aromatic amines, treatment with chemotherapy agents, including cyclophosphamide and acrolein, and pelvic irradiation [8].

The majority of patients present with superficial disease, and treatment of bladder cancer is based on the TNM staging system. Non-muscle-invasive, high grade disease (carcinoma in situ, T1) is treated with transurethral bladder resection and intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy. Radical cystectomy with or without neoadjuvant or adjuvant cisplatin-based chemotherapy or a bladder-preservation approach with chemoradiation is used in the management of locally advanced disease. Platinum-based cytotoxic combination regimens are used in advanced disease. While gemcitabine and cisplatin (GC) does not improve overall survival compared with the combination of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC), MVAC is associated with increased toxicity, including granulocytopenia, nausea, and vomiting. Therefore, GC is generally favored [9]. However, these strategies are clearly inadequate. Seventy percent of patients with superficial disease relapse, between 10 and 30% will eventually progress to muscle-invasive disease, and half of all patients with resected, locally advanced disease die from metastatic disease within 2 years [10]. The prognosis of patients with advanced disease is extremely poor with median survival of 14 months despite optimal cisplatin-based combination chemotherapy [9].

Molecular pathways

Bladder cancer represents a unique opportunity to study the progression of genetic aberrations across stages as tissue is frequently accessible. A well-described signature of chromosomal aberrations exists between low-grade, non-invasive, papillary hyperplasia variants and high-grade, muscle-invasive disease. However, despite a detailed understanding of the molecular pathogenesis of urothelial carcinoma, translating this knowledge into clinical biomarkers and effective therapies has been challenging and elusive. As discussed by Bryan et al. in their review of molecular pathways in bladder cancer, the genetic changes in low-grade and high-grade urothelial carcinoma promote the six “hallmarks” of cancer outlined by Hanahan and Weinberg: 1) self-sufficiency in growth signals, 2) insensitivity to anti-growth signals, 3) evasion of apoptosis, 4) limitless replicative potential, 5) sustained angiogenesis, and 6) tissue invasion and metastasis [11-14].

The most frequent activating mutations detected in low-grade tumors constitutively up-regulate the activity of receptor-tyrosine kinase-Ras pathway and include over-expression of fibroblast growth factor receptor-3 (FGFR-3) in up to 70% of tumors [15], HRAS in 30-40% [16] and PIK3CA in 10% [17]. Chromosome 9 loss is seen in both low-grade and high-grade

tumors [18]. The deletion or mutation of tumor suppressor genes *p53* [19] and *pRB* [20], both critical cell cycle regulators, are the most frequent abnormalities in high-grade tumors and contribute to tumor progression. High grade lesions may also have *PTEN* [21] and *p16* [22] loss as well. Finally, changes in the microenvironment also promote invasion and progression through aberrant N- and E-cadherin expression [23] and production of vascular endothelial growth factor [24].

Targeted therapy

The results of clinical trials of targeted agents for urothelial cancers published thus far have generally been disappointing, and to date, no biologic agents have been approved either as monotherapy or in combination with cytotoxic chemotherapy for advanced UC. Despite the identification of genetic alterations thought to drive high-grade, muscle-invasive disease, these aberrations have not successfully predicted response to targeted treatment. Classes of agents in recent and ongoing clinical trials include antiangiogenic monoclonal antibodies; multitargeted tyrosine kinase inhibitors against VEGFR2 and PDGFR; EGFR and HER2 inhibitors; and other inhibitors targeted against mTOR, FGFR3, IGFR1 and Src. Novel vaccine strategies are also being employed.

Angiogenesis inhibitors

Angiogenesis is an attractive target in urothelial cancer given the roles of the pro-angiogenic factors VEGF, FGF and PDGF in cell cycle regulation and invasion [25]. In addition, VEGFR and EGFR inhibition may sensitize to cisplatin [26,27]. Hahn et al. recently reported the mature results of their phase II study of bevacizumab with cisplatin and gemcitabine as first-line therapy for metastatic urothelial carcinoma [28] (Table 1). The overall response rate was 72% with 9 complete responses and 22 partial responses out of 43 patients. Median progression free survival was 8.2 months with a median overall survival of 20.4 months; however, this study failed to meet its primary endpoint. Toxicities were consistent with recognized effects of anti-angiogenesis treatment and included DVT/PE (21%), hemorrhage (7%), hypertension (5%), and proteinuria (2%). Based on these results, a CALBG phase III trial comparing first-line gemcitabine and cisplatin with or without bevacizumab is currently underway (NCT00942331), as well as a phase II first-line study of gemcitabine, carboplatin and bevacizumab in patients who are ineligible for cisplatin (NCT00588666) (Table 1). The triplet of gemcitabine, cisplatin and bevacizumab is also being studied in the neoadjuvant setting in a phase II study for locally advanced UC prior to radical cystectomy (NCT00268450) (Table 1).

The VEGF receptor fusion protein VEGF-Trap (Aflibercept) targets placental growth factor and has greater affinity for VEGF than bevacizumab. This agent was well-tolerated in platinum-pretreated patients with transitional cell carcinoma but had limited single-agent activity with a response rate of 4.5% and progression-free survival of 3.5 months [29] (Table 1).

Sunitinib is a multitargeted tyrosine kinase inhibitor with activity against VEGF, PDGFR, Kit, FLT3 and RET. It showed modest activity in a phase II trial in previously-treated urothelial cancer with clinical regression or stable disease in 43% of patients and which lasted longer than 3 months in 29% of patients (Table 1); overall survival was approximately 7 months [30]. Given its activity against urothelial cancer, sunitinib was also studied in the first-line setting together with gemcitabine and cisplatin. While preliminary data suggest antitumor activity with 9 of 15 patients having partial responses or stable disease, toxicity was limiting. Specifically, 6 of 15 patients discontinued treatment early, most commonly due to cytopenias, and 33% experienced a serious adverse event, including one death due to neutropenic sepsis [31] (Table 1). Sorafenib, a multikinase inhibitor with activity against

VEGFR, PDGFR, Kit and RAF, showed no objective responses in first-line treatment of metastatic urothelial cancer with time to progression of 1.9 months and median survival of 5.9 months [32] (Table 1). In the second-line setting, sorafenib also failed to produce any objective responses [33] (Table 1).

Pazopanib is a tyrosine kinase inhibitor that selectively targets VEGF, PDGFR and Kit to inhibit angiogenesis. Preliminary results of this agent in a phase II trial of single-agent pazopanib in relapsed or refractory advanced urothelial carcinoma, which included 8 cases of upper urinary tract disease, demonstrated 4/18 patients with partial responses and 11/18 with stable disease (83% clinical benefit) after a median follow-up of 3 months (NCT01031875) [34] (Table 1). Other ongoing trials are investigating the role of pazopanib in the second-line setting for advanced, platinum-refractory urothelial carcinoma in combination with vinflunine (NCT01265940) and weekly paclitaxel (NCT01108055) (Table 1). A phase II trial of single-agent pazopanib in second-line metastatic urothelial carcinoma was recently completed but not yet reported (NCT00471536) (Table 1).

Growth factor inhibitors

Members of the ErbB or epidermal growth factor receptor (EGFR) protein family of receptors and their ligands, including epidermal growth factor (EGF) and fibroblast growth factor-3 (FGF-3), as well as type 1 insulin-like growth factor receptor (IGF1R) and insulin-like growth factor (IGF) in the IGF axis, are potential targets in the treatment of urothelial cancers given reports of over-expression in advanced disease [35-37]. Results from in vitro and preclinical studies confirm the role of EGFR and HER2/neu in the proliferation of bladder cancer cells and support the rationale to target these receptors in clinical trials with small molecule tyrosine kinase inhibitors (TKIs) [38-41].

Petrylak et al. recently reported the disappointing results that ZD1839 (gefitinib), an oral EGFR TKI, was ineffective as second-line therapy for metastatic transitional cell carcinoma based on the results of their Southwest Oncology Group phase II study (S0031) [42] (Table 2). They found that despite strong expression of EGFR staining in nearly half of the pretreatment biopsies reviewed, only 2 patients survived past 6 months without disease progression and the median progression-free survival was 2 months. Similarly, the results of CALBG 90102, a phase II evaluation of cisplatin, gemcitabine and gefitinib as first-line treatment for advanced urothelial carcinoma, showed no improvement in response rates or survival compared to historical controls who received gemcitabine and cisplatin [43] (Table 2).

Erlotinib, another EGFR TKI, has shown evidence of activity in a phase II trial of neoadjuvant treatment in patients with muscle-invasive bladder cancer undergoing radical cystectomy [44] (Table 2). Five of 20 patients with clinical stage T2 were found to have pT0 disease following treatment, 7 were clinically down-staged ($\leq$ pT1) and 15 had organ-confined disease at surgical pathology. At 24.8 months of follow-up, 14 remained alive, of whom 10 had no evidence of disease, and 4 had disease progression. However, the 50% DFS at 2 years with erlotinib was comparable to historical data from patients with clinical T2 disease who underwent surgery alone. No published data for erlotinib in the metastatic setting is available. An alternative strategy to target EGFR employs the use of cetuximab, a chimeric monoclonal antibody against the receptor. Cetuximab is currently being studied in combination with gemcitabine and cisplatin in a phase II trial of previously untreated patients with advanced urothelial carcinoma (NCT00645593) (Table 2).

As with EGFR, HER2/neu overexpression has been targeted therapeutically. Lapatinib, a dual TKI of EGFR and HER2/neu, was studied in a phase II trial as second-line therapy for patients with advanced transitional cell carcinoma [45] (Table 2). The overall response rate

was 1.7% and 31% of patients had stable disease. While the median overall survival was 17.9 weeks, patients with EGFR or HER2 overexpression appeared to benefit the most from therapy with a median overall survival of 30.3 weeks compared to 10.6 for those patients with low expression. A phase II/III study of lapatinib as second-line therapy for advanced urothelial cancer is ongoing (NCT00949455), as well as a study sponsored by the EORTC in the first-line setting together with gemcitabine and cisplatin (NCT00623064) (Table 2).

The HER2/neu monoclonal antibody trastuzumab was assessed in combination with paclitaxel, carboplatin and gemcitabine in a first-line, phase II trial that required overexpression of HER2/neu by immunohistochemistry, gene amplification or serology [46] (Table 2). Thirty-one of 44 patients (70%) responded with 5 complete responses, and median time to progression and overall survival were 9.3 and 14.1 months respectively. Twenty-two percent experienced grade 1-3 cardiac toxicity, though only 3 patients of 44 experienced grade 3 cardiac toxicity. Trastuzumab is being studied together with paclitaxel and radiation for patients ineligible for cystectomy (NCT00238420) and studies of a novel Fc-optimized monoclonal antibody that targets HER2, MGAH22, are in phase I trials (NCT01195935, NCT01148849) (Table 2).

Multiple groups have speculated on the discouraging lack of efficacy of gefitinib and lapatinib in urothelial carcinoma despite EGFR and HER2 overexpression. In the case of EGFR, Blehm et al. examined 11 urothelial bladder cancer cell lines and 75 patient tumors for the presence of mutations within the kinase domain and expression of EGFRvIII expression, which have been reported to affect patient response to gefitinib [47,48]. They failed to detect kinase domain mutations and expression of EGFRvIII and concluded that the rare presence of these alterations in bladder cancer could reduce the rate of response to TKI therapy. Gallucci et al. found a significantly lower rate of HER2 gene amplification than HER2 protein expression or chromosome 17 polysomy [49] and suggested that the form of overexpression could affect response to targeted therapy [50], an issue that has been raised in the breast cancer literature as well [51].

The process of epithelial-to-mesenchymal transition (EMT) has also been suggested to play a role in promoting resistance of bladder cancer cells to EGFR inhibitors. Using global gene expression profiling, McConkey et al. showed that human urothelial carcinoma cell lines segregated into “epithelial” and “mesenchymal” subsets where the “epithelial” subset was sensitive to EGFR inhibitors [52]. Furthermore, EGFR resistance in the “mesenchymal” lines could be reversed by expression of the microRNA-200 family (see “Future Perspective” below for description of microRNAs), which restored an “epithelial” phenotype characterized by increased levels of E-cadherin; decreased expression of ZEB1, ZEB2, and ERFFI-1; and decreased cell migration [53]. These findings warrant further clinical investigation into the role of EMT and miR200 targets as predictive markers for sensitivity to EGFR inhibition and may present a novel pathway to reverse resistance in urothelial carcinoma.

As previously mentioned, FGFR-3 and IGF1R are known to be over-expressed in urothelial carcinoma with rates of 60-70% in some series and thus may represent clinically useful therapeutic targets [36]. TKI12458 from Novartis is currently being studied in a phase II trial (NCT00790426) of second and third-line therapy for patients with FGFR-3 mutated and wild type urothelial carcinoma after it demonstrated activity in preclinical models [54] (Table 2). IGF1R has been shown to promote motility and invasion through AKT- and mitogen-activated protein kinase (MAPK)-dependent activation of paxillin [55]. Cixutumumab is a monoclonal antibody against IGF1R currently in development [56].

Src and mTOR inhibitors

Dasatinib, a Src-inhibitor that down-regulates the AKT pathway, showed antitumor activity in vitro against Src-overexpressing transitional cell carcinoma cell lines and was active in combination with cisplatin in a murine xenograft [57]. Based on these preclinical findings, the Hoosier Oncology Group (HOG) is conducting a trial of neoadjuvant dasatinib prior to radical cystectomy for urothelial carcinoma of the bladder (NCT00706641) [57]. In addition to AKT, other active pathways implicated in the pathogenesis of urothelial carcinoma include PI3K and PTEN [58,59]. Down-regulation of PTEN is seen in over 20% of muscle-invasive bladder tumors and in up to 40% of tumors in the presence of p53 mutations, and inactivation of this pathways results in loss of control of the mTOR signaling cascade [21]. Everolimus (RAD001), a selective mTOR inhibitor, is currently being assessed in a phase II trial in second-line therapy for advanced urothelial carcinoma [60] (NCT00805129), as well as in a phase II, second-line trial in combination with paclitaxel for advanced disease (NCT00933374), and a phase II first-line study with or without paclitaxel for patients who are ineligible for cisplatin (NCT01215136).

Hormone therapy

Urothelial carcinomas express estrogen receptor (ER), with rates of up to 80% in some series [61]. While the relationship between ER expression and grade of the tumor is inconsistent [62], ER has been shown to mediate estrogen-induced urothelial cell proliferation [63]. A case report in the urological literature describes a patient with metastatic urothelial carcinoma who received tamoxifen, a selective estrogen receptor mediator (SERM), for gynecomastia and whose cancer regressed while on this therapy [64]. Preclinical work with SERMs in a murine model demonstrated inhibition of transitional cell xenografts [65]. Based on this data, and the relatively low toxicity profile, two phase II trials at Baylor are assessing tamoxifen in the second-line setting for advanced urothelial cell carcinoma (NCT00589017 and NCT00710970).

Immune therapy

Stimulation of the immune system with BCG is the standard of care for the treatment of non-muscle-invasive bladder cancer [7]. While significant differences exist between noninvasive and invasive disease, this strategy raises the possibility that the immune system may be potentiated to recognize advanced urothelial carcinoma. Carthon et al. recently reported the results of a neoadjuvant study assessing the effects of ipilimumab, an anti-cytotoxic T lymphocyte associated antigen (CTLA-4) antibody, on localized urothelial carcinoma of the bladder [66]. They found that in patients with localized UC of the bladder, a brief exposure to anti-CTLA-4 with either 3 mg/kg/dose or 10 mg/kg/dose for two doses prior to surgery was safe and following therapy with anti-CTLA-4 was associated with an increased frequency of CD4⁺ICOS^{hi} T cells in systemic circulation and bladder tumor tissue. They then retrospectively correlated the frequency of CD4⁺ICOS^{hi} T cells with clinical benefit in a cohort of metastatic melanoma patients and found that increased frequency of CD4⁺ICOS^{hi} T cells in tumor tissues and systemic circulation correlated with increased likelihood of overall survival. This result has not yet been reported for urothelial carcinoma.

A vaccine against survivin, an inhibitor of apoptosis protein (IAP) that targets caspases, was recently tested in a phase I trial that enrolled 9 patients, and the survivin-2B80-88 peptide vaccine was shown to be safe without any adverse events reported [67]. While this trial was not designed to assess clinical efficacy, one patient experienced a slight reduction in tumor burden, and five patients had a significant increase in the peptide-specific CTL frequency. Human chorionic gonadotropin-beta (hCG-β) can be produced by urothelial carcinomas and

is the target of a dendritic cell vaccine, CDX-1307, in an on-going, randomized, phase II neoadjuvant study of resectable, muscle-invasive, hCG- β^+ bladder cancer [68]. NY-ESO-1, a protein produced by multiple tumor types, is the target of a phase I/II vaccine study together with immune stimulants Resiquimod and poly-ICLC (Hiltonol) in patients with urothelial carcinomas that express NY-ESO-1 (NCT00948961).

Novel chemotherapy agents

While there has been considerable focus on the testing of targeted therapies in urothelial carcinomas, the lack of efficacy of these agents limits applications in routine clinical practice, and therefore traditional cytotoxic chemotherapy remains the only proven strategy for advanced disease. Urothelial cancer is chemo-sensitive with response rates of up to 70% for first-line combination gemcitabine and cisplatin or M-VAC. However, nearly 85% of cases relapse, at which point response rates to taxanes, often used as second-line therapy, fall to 10-20% with progression-free survival of 2-3 months and overall survival of 6-9 months [69]. Multiple studies are investigating novel chemotherapy agents and significant efforts are focused on elucidating the mechanism of platinum resistance, currently the most active family of therapeutics against urothelial carcinoma. The “one-size-fits-all” approach is not applicable in the salvage setting given that individual patients may have residual toxicities from prior regimens, such as peripheral neuropathy secondary to platinum use, and tumor biology and chemosensitivity are altered due to selective pressure following exposure to first-line treatment.

A number of agents with proven activity in other malignancies have been tested against urothelial carcinoma, both as single-agents as well as in combination with gemcitabine and cisplatin, such as oxaliplatin [70-72], docetaxel [73-75], ifosfamide [76,77] and the proteasome inhibitor bortezomib [78,79]. None of these agents demonstrated improved response rates, progression-free survival or overall survival as compared to standard gemcitabine and cisplatin for first-line treatment and in the second-line setting had only minimal, or no, activity, as in the case of bortezomib. Novel chemotherapy agents recently or currently in testing include *Vinca* alkaloids, microtubule dynamics inhibitors, nanoparticle taxanes, epothilones, antifolates, and histone deacetylase inhibitors.

Vinflunine

In 2009, vinflunine, the microtubule-inhibiting *Vinca* alkaloid, gained approval by the European Medicines Agency as the first agent in the treatment of metastatic urothelial carcinoma after failure of a prior platinum-containing regimen. Preclinical work dating from 2002 demonstrated activity in an orthotopic murine bladder cancer model [80]. A small phase II trial in 2006 of vinflunine as second-line monotherapy showed a response rate of 18% with a median duration of response of 9.1 months despite the inclusion of patients with relatively poor prognostic factors including short interval since first-line therapy (19%, <12 months) and visceral involvement (20%) [81]. Vaughn et al. conducted a larger phase II study with 175 patients that demonstrated a response rate of 15% and median duration of response of 6 months [82]. This was followed by a phase III trial by Belmunt et al. of 370 patients of whom 70% progressed within 6 months of first-line platinum therapy and 80% had visceral disease [83]. In this setting, vinflunine compared with best supportive care (BSC) produced a significant response rate of 8.6 vs 0% and median progression free survival of 3.0 vs 1.5 months. While the intention-to-treat analysis showed only a trend towards improved survival with vinflunine compared with BSC, multivariate Cox analysis adjusted for prognostic factors confirmed a reduction in the risk of death by 23% and a statistically significant increase in overall survival with vinflunine.

Eribulin

Initially derived from the black Pacific marine sponge *Halichondria okadai* Kadota in 1986, the cytotoxic properties of halichondrin B were recognized by Hirata and Uemura in their initial report [84]. Eribulin (E7389) was subsequently developed as a synthetic analog of halichondrin B, and it inhibits microtubule growth resulting in cell cycle arrest. The results of a phase II study demonstrated a response rate in patients with neoadjuvant chemotherapy of 34% and median progression free survival of 3.9 months with median overall survival of 9.4 months [85]. This agent is being studied as first-line therapy in combination with gemcitabine and cisplatin (NCT01126749) and as second-line treatment for patients with renal dysfunction (NCT00365157).

Taxanes

Nab-paclitaxel is an albumin-bound, nanoparticle formulation of paclitaxel (Abraxane) that utilizes an albumin receptor on the endothelial cell surface and accumulates in the tumor interstitium [86]. Sridhar et al. recently reported the results of a phase II trial of nab-paclitaxel as second-line therapy for patients with metastatic urothelial carcinoma that demonstrated an overall response rate of 31% with another 41% of patients experiencing stable disease, for a disease control rate (RR plus stable disease) of 72% [87]. Based on these promising results, the study is accruing an additional 19 patients for a total of 48.

Epothilones

Epothilones are a novel class of antineoplastic agents with activity against cells that have acquired resistance to taxanes through beta-tubulin mutation or overexpression by enhanced microtubule stability via tubulin polymerization, which leads to cell cycle arrest at the G2/M transition and ultimately apoptosis [88]. The epothilone analogue Ixabepilone (BMS-247550) was found to have very modest activity against urothelial carcinoma with a response rate of 11.9% as second-line therapy in E3800, an Eastern Cooperative Oncology Group (ECOG) study [89]. The combination of gemcitabine and BMS-247550 was assessed in a phase I study and had high rates of dose-limiting myelosuppression [90].

Antifolates

Methotrexate, an antifolate with known activity against urothelial carcinoma, is administered together with vinblastine, doxorubicin and cisplatin as part of the MVAC regimen. There have been a number of studies of pemetrexed, a multitargeted antifolate, in combination with gemcitabine as first-line therapy [91,92] or as monotherapy in the second-line setting [93,94]. This agent demonstrated a tolerable side-effect profile and moderate activity, though was not superior to single-agent gemcitabine. While there are no current studies of pemetrexed for urothelial carcinoma, its analog, pralatrexate is being assessed in a phase II, second-line trial in combination with folic acid and vitamin B12 (NCT00722553).

Histone deacetylase inhibitors

While its mechanism of action remains unknown, vorinostat (suberoylanilide hydroxamic acid; NSC 701852), a histone deacetylase inhibitor (HDI), was licensed by the FDA in 2006 for the treatment of cutaneous T cell lymphoma. A phase I trial of this agent in advanced solid malignancies, including bladder cancer, was terminated due to toxicity (NCT 00565227). A phase II study of single-agent vorinostat in the second-line setting demonstrated a best response of stable disease in 3/12 patients and was associated with significant toxicity, primarily cytopenias and thrombocytopenic hemorrhage, including five grade 4/5 events, four grade 3, and two early on-study deaths [95].

Biomarkers of cisplatin resistance

In light of the strikingly limited numbers of therapeutic agents with documented activity against urothelial carcinoma, an understanding of the mechanisms of resistance to platinum compounds is essential, and strategies to circumvent this obstacle remain an unmet need. Cisplatin and its less toxic second generation analogue carboplatin share the same mechanism of action and cross-resistance, in contrast to the analog oxaliplatin, which has a different mechanism and consequently does not share cross-resistance [96]. Platinums bind to DNA and form monoadducts, which usually react to create intra- and inter-strand crosslinks that contort the conformation of the double helix. These DNA lesions ultimately block transcription and replication and activate signaling cascades, including caspases, thus resulting in cytotoxicity via apoptosis.

Human cells have six major DNA repair pathways: nucleotide excision repair (NER), mismatch repair (MMR), homologous recombination (HR), non-homologous end-joining (NHEJ), base excision repair (BER) and translesion synthesis (TLS) [97]. While defects in any one of these pathways can cause mutations, genomic instability and predispose to the development of malignancy, sensitivity of tumor cells to chemotherapy relies upon the same pathways. Conversely, alteration of DNA repair pathways can lead to chemoresistance. Emerging data suggests that NER, HR and MMR are involved in mediating chemosensitivity and resistance to platinum agents in urothelial carcinomas.

Nucleotide excision repair and ERCC1

NER removes platinum adducts that distort the DNA helix. Excision repair cross-complementation group 1 (ERCC1) is required to excise the damaged nucleotide and this allows DNA polymerase to resynthesize the section [98]. Multiple studies have demonstrated that reduced levels of ERCC1 are associated with sensitivity to cisplatin in testicular germ cell tumors [99]. Furthermore, chemosensitivity can be restored in cisplatin-resistant ovarian cancer cell lines with elevated levels of ERCC1 via antisense RNA inhibition of ERCC1 [100]. ERCC1 was shown to predict response to cisplatin-based chemotherapy in advanced bladder cancer patients treated with gemcitabine plus cisplatin; patients with low levels of ERCC1 mRNA expression had a median survival of 25.4 months versus 15.4 months in those with high levels of expression [101]. In addition, univariate and multivariate analyses with pretreatment prognostic factors demonstrated that ERCC1 levels were also independently associated with survival. However, it is difficult to determine whether ERCC1 is a predictive or prognostic factor, since it likely mediates response to platinum agents. The same group recently reported that ERCC1 expression by immunohistochemistry was predictive of disease-specific survival in patients with advanced urothelial carcinoma who received cisplatin chemotherapy [102]. Patients with no expression of ERCC1 had a median disease-specific survival of 12.6 months versus 8.6 months for those with high expression.

Mismatch repair and p53

Similar to NER, MMR is also initiated by the detection of DNA damage and results in the excision of mismatched nucleotides or insertion/deletion loops, followed by resynthesis of the missing portion by DNA polymerase [98]. Unexpectedly, however, MMR deficiency is associated with cisplatin resistance [103]. It is possible that MMR recognition of DNA damage or the process of excision itself triggers apoptosis [97]. While a predictive biomarker involved in the MMR pathway has not been identified and tested in the setting of urothelial carcinoma, a new report suggests that mutations in mismatch repair genes known to cause Lynch syndrome, which is associated with upper tract transitional cell carcinomas, may also pose an increased risk of bladder cancer [104]. Furthermore, it has been

hypothesized that defects in the DNA repair pathway, including MMR, may mediate the increased risk of bladder cancer secondary to the known carcinogenic effects of tobacco use [105,106]. Therefore, in addition to likely mediating cisplatin resistance in urothelial carcinomas, defects in the MMR pathway may be involved in pathogenesis as well.

The tumor suppressor gene *p53* has long been hypothesized to be a key player in the pathogenesis of invasive urothelial carcinoma, and preclinical studies support the role of *p53* inactivation in urothelial proliferation and invasion [21,107]. While *p53* is not directly involved in MMR, loss of both *p53* and MMR function results in rapid evolution of cisplatin resistance in a human colon carcinoma cell line treated with cisplatin likely via increased mutagenic translesion synthesis [108]. A prospective trial incorporating *p53* status in the selection of adjuvant chemotherapy for patients with muscle-invasive, node negative urothelial carcinoma following radical cystectomy failed to demonstrate prognostic or predictive value of *p53* immunohistochemistry, though the study was compromised by failure to receive the assigned therapy in many patients and a lower than expected event rate, with a 5 year relapse free survival of 80% [109]. In contrast, a recent report of over 3,000 patients demonstrated that *p53* had predictive value in advanced bladder cancer but in not superficial (Ta) disease [110]. As a mechanism to overcome platinum resistance, overexpression of *p53* through adenoviral gene transfer has been successful in human bladder cancer cell lines and demonstrated synergy with cisplatin [111]. Adenoviral *p53* gene transfer has also been combined with the use of antisense oligodeoxynucleotide targeting of the anti-apoptotic gene clusterin in a bladder cancer model in nude mice where it resulted in eradication of tumors and lymph node metastases following treatment with cisplatin, suggesting that this strategy may have clinical efficacy [112].

Homologous recombination and BRCA1

The tumor suppressor gene breast-cancer-susceptibility gene 1 (*BRCA1*) together with proteins mutated in Fanconi's anemia (FA proteins), a rare inherited condition of chromosomal instability, are involved in the DNA repair pathway of homologous recombination (HR), which causes resistance to DNA inter-strand cross-links [113]. Homologous recombination involves the exchange of nucleotide sequences between identical strands of DNA. *BRCA1* binds to the protein encoded by breast-cancer susceptibility gene 2 (*BRCA2*), which was surprisingly found to be the same protein as FANCD1, an FA protein, and this complex is recruited to sites of DNA damage due to inter-strand cross-links [114]. Decreased expression of *BRCA1* has been associated with increased cisplatin sensitivity in a number of tumors, including breast and ovarian [115,116], whereas those with elevated *BRCA1* levels had better outcomes with taxanes compared to those with low levels in ovarian cancer and non-small cell lung cancer [115,117].

BRCA1 mRNA expression was recently tested as a predictive marker for response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive, locally advanced bladder cancer [118]. Among patients with low to intermediate expression of *BRCA1*, 66% (24 of 39) achieved a significant pathological response of pT0-1 compared with 22% (4 of 18) of patients with high *BRCA1* expression. Furthermore, the 5 year survival rate of 64% for patients with low to intermediate expression of *BRCA1* was significantly improved compared to 12% for those with the highest level of *BRCA1* expression. Based on these clinical studies as well as preclinical data from cell lines that also demonstrate an inverse relationship between *BRCA1* levels and resistance to cisplatin/taxane [119], *BRCA1* is a candidate predictive marker in selecting chemotherapy for individuals with urothelial carcinoma.

Future Perspective

The extraordinary potential of personalized therapy in the fight against cancer has been recognized by the National Cancer Institute through their distribution of nearly \$1.3 billion in Recovery Act funds over 2009 and 2010 to programs that support the Personalized Cancer Care/Drug Development Platform, including The Cancer Genome Atlas (TCGA), Cancer Human Biobank (CaHUB), and Accelerating Clinical Trials of Novel Oncologic Pathways (ACTNOW). While money alone will not lead to scientific advancement, it is clear that progress in oncology is dependent upon collaborations across disciplines that will be supported by these funds. In the case of urothelial malignancies, identification of many of the driving genetic aberrations underlying its molecular pathogenesis has not yet translated into progress in the application of clinically useful biomarkers [120] or treatment options for this disease. Findings from the emerging field of microRNAs may result in novel biomarkers and reveal mechanisms of cancer pathogenesis that can be exploited as therapeutic targets.

MicroRNAs (miRNAs) are abundant small (~20-22 nts) non-coding RNAs that typically dampen gene expression at the post-transcriptional level [121,122] and are mis-expressed in a variety of cancer cells [123]. Early studies of miRNAs in cancer pathogenesis suggest that miRNA expression patterns (termed ‘signatures’) may be more reliable than mRNA profiles in the identification and/or classification of tumors [124]. Unlike the vast number of mRNAs, there are only ~1000 miRNAs in the human genome, and a modest number of miRNAs may be sufficient to serve as markers to differentiate a specific tumor [125]. Also, miRNAs are distinctly more stable than mRNAs and are easily recovered and detected in paraffin embedded tissue [125]. The use of miRNA ‘signatures’ as predictive markers and potential modulators of cancer therapy is being explored for different cancers [126], and results in breast cancer suggest utility of miRNA signatures in predicting sensitivity to both chemo- and endocrine therapy [127][128]. Although complementary clinical data is still largely lacking, one example in epithelial ovarian cancer revealed a set of 34 miRNAs that were differentially expressed in patients who responded to platinum-based chemotherapy versus non-responders [129].

Despite the large numbers of patients affected by urothelial cancers, progress has been impeded by low rates of enrollment in clinical trials. Furthermore, as a disease of older patients, many present with substantial medical comorbidities that limit trial eligibility and treatment options. As discussed by Gonzalez-Angulo et al. in their article “Future of Personalized Medicine in Oncology: A Systems Biology Approach,” large randomized studies, which are regarded as the highest level of evidence in medicine, inform treatment decisions for the average patient but not individual patients [130]. In an effort to improve predictions of chemosensitivity, Lee et al. recently reported on the development and application of a generic algorithm they named “coexpression extrapolation” (COXEN) that is based on molecular profiling data from the NCI-60 panel and suggest that this could be used for *in silico* drug discovery and tailoring chemotherapy selection for individual patients [131,132].

Novel clinical trial strategies that incorporate molecular profiling information are needed in order to enrich trials with patients who have the greatest chance of responding to rationally designed therapeutic agents, as well as rigorously test potential biomarkers [133]. In addition, this approach will hopefully reduce toxicity through personalized drug dosing based on metabolism and molecular crosstalk. The “brief-duration, biomarker-driven” neoadjuvant strategy could streamline drug development, though results may not predict efficacy in the advanced setting [69].

To date, results of clinical trials of targeted therapies and novel cytotoxics have not improved the outlook for patients with advanced urothelial carcinoma despite the rationale selection of targets and agents. Practice-changing breakthroughs remain dependent upon identification of novel therapeutic targets, improved molecular prognostic markers to predict responses for the available active agents, and clinical trial participation for all eligible patients.

Acknowledgments

The authors gratefully acknowledge the Bladder Cancer Advocacy Network (BCAN), which supported this work.

References

- [1]. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N. Engl. J. Med.* 2004; 351(27):2817–2826. [PubMed: 15591335]
- [2]. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N. Engl. J. Med.* 2005; 353(16):1673–1684. [PubMed: 16236738]
- [3]. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N. Engl. J. Med.* 2010; 363(9):809–819. [PubMed: 20818844]
- [4]. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J. Clin. Oncol.* 2009; 27(26):4247–4253. [PubMed: 19667264]
- [5]. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. *CA Cancer. J. Clin.* 2010; 60(5):277–300. [PubMed: 20610543]
- [6]. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. *Urology.* 2006; 68(3):549–553. [PubMed: 16979735]
- [7]. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? *CA Cancer. J. Clin.* 2010; 60(4):244–272. [PubMed: 20566675] * Comprehensive overview of the current state of detection, surveillance and treatment of bladder cancer, as well as a succinct summary of aberrations that characterize pathways of urothelial tumorigenesis.
- [8]. Golijanin DJ, Kakiashvili D, Madeb RR, et al. Chemoprevention of bladder cancer. *World J. Urol.* 2006; 24(5):445–472. [PubMed: 17048030]
- [9]. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J. Clin. Oncol.* 2005; 23(21):4602–4608. [PubMed: 16034041]
- [10]. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. *J. Urol.* 2002; 167(4):1573–1583. [PubMed: 11912367]
- [11]. Bryan RT, Hussain SA, James ND, et al. Molecular pathways in bladder cancer: part 1. *BJU Int.* 2005; 95(4):485–490. [PubMed: 15705065]
- [12]. Bryan RT, Hussain SA, James ND, et al. Molecular pathways in bladder cancer: part 2. *BJU Int.* 2005; 95(4):491–496. [PubMed: 15705066]
- [13]. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000; 100(1):57–70. [PubMed: 10647931]
- [14]. Lindgren D, Gudjonsson S, Jee KJ, et al. Recurrent and multiple bladder tumors show conserved expression profiles. *BMC Cancer.* 2008; 8:183. [PubMed: 18590527]
- [15]. Barbisan F, Santinelli A, Mazzucchelli R, et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. *Cancer.* 2008; 112(3):636–644. [PubMed: 18072261]
- [16]. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. *Oncogene.* 2001; 20(16):1973–1980. [PubMed: 11360181]

- [17]. Lopez-Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. *Cancer Res.* 2006; 66(15):7401–7404. [PubMed: 16885334]
- [18]. Kawauchi S, Sakai H, Ikemoto K, et al. 9p21 Index as Estimated by Dual-Color Fluorescence in Situ Hybridization is Useful to Predict Urothelial Carcinoma Recurrence in Bladder Washing Cytology. *Hum. Pathol.* 2009; 40(12):1783–1789. [PubMed: 19733894]
- [19]. George B, Datar RH, Wu L, et al. P53 Gene and Protein Status: the Role of P53 Alterations in Predicting Outcome in Patients with Bladder Cancer. *J. Clin. Oncol.* 2007; 25(34):5352–5358. [PubMed: 18048815]
- [20]. Cormio L, Tolve I, Annese P, et al. Retinoblastoma protein expression predicts response to bacillus Calmette-Guerin immunotherapy in patients with T1G3 bladder cancer. *Urol. Oncol.* 2010; 28(3):285–289. [PubMed: 18976938]
- [21]. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. *Genes Dev.* 2009; 23(6):675–680. [PubMed: 19261747]
- [22]. Bartoletti R, Cai T, Nesi G, et al. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. *J. Surg. Res.* 2007; 143(2):422–427. [PubMed: 17612565]
- [23]. McConkey DJ, Lee S, Choi W, et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. *Urol. Oncol.* 2010; 28(4):429–440. [PubMed: 20610280]
- [24]. Garcia-Closas M, Malats N, Real FX, et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. *PLoS Genet.* 2007; 3(2):e29. [PubMed: 17319747]
- [25]. Nakanishi R, Oka N, Nakatsuji H, et al. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. *Urol. Int.* 2009; 83(1):98–106. [PubMed: 19641368]
- [26]. Flaig TW, Su LJ, McCoach C, et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. *BJU Int.* 2009; 103(12):1729–1737. [PubMed: 19220256]
- [27]. Li Y, Yang X, Su LJ, et al. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. *Oncol. Rep.* 2010; 24(4):1019–1028. [PubMed: 20811684]
- [28]. Hahn NM, Stadler WM, Zon R, et al. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). *J. Clin. Oncol.* 2010; 28(15s)
- [29]. Twardowski P, Stadler WM, Frankel P, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. *Urology.* 2010; 76(4):923–926. [PubMed: 20646741]
- [30]. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. *J. Clin. Oncol.* 2010; 28(8):1373–1379. [PubMed: 20142593]
- [31]. Galsky MD, Sonpavde G, Hellerstedt BA, et al. Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC). *ASCO Meeting Abstracts.* 2010; 28(15_suppl):4573.
- [32]. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. *Invest. New Drugs.* 2010
- [33]. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. *Cancer.* 2009; 115(18):4090–4095. [PubMed: 19536901]
- [34]. Necchi A, Nicolai N, Guglielmi L, et al. Phase II study of pazopanib monotherapy for patients with relapsed/refractory urothelial cancer (INT70/09, NCT01031875). *Ann. Oncol.* 2010; 21(Suppl 8):viii11.

- [35]. De Boer WI, Houtsmuller AB, Izadifar V, et al. Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. *Int. J. Cancer*. 1997; 71(2):284–291. [PubMed: 9139855]
- [36]. Rochester MA, Patel N, Turney BW, et al. The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. *BJU Int*. 2007; 100(6):1396–1401. [PubMed: 17645417]
- [37]. Gardmark T, Wester K, De la Torre M, et al. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. *BJU Int*. 2005; 95(7):982–986. [PubMed: 15839918]
- [38]. Dominguez-Escrig JL, Kelly JD, Neal DE, et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. *Clin. Cancer Res*. 2004; 10(14):4874–4884. [PubMed: 15269164]
- [39]. Nagasawa J, Mizokami A, Koshida K, et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. *Int. J. Urol*. 2006; 13(5):587–592. [PubMed: 16771730]
- [40]. Nutt JE, Lazarowicz HP, Mellon JK, et al. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. *Br. J. Cancer*. 2004; 90(8):1679–1685. [PubMed: 15083203]
- [41]. McHugh LA, Kriajevska M, Mellon JK, et al. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. *Urology*. 2007; 69(2):390–394. [PubMed: 17320695]
- [42]. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. *BJU Int*. 2010; 105(3):317–321. [PubMed: 19888985]
- [43]. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. *Ann. Oncol*. 2009; 20(6):1074–1079. [PubMed: 19168670]
- [44]. Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. *BJU Int*. 2010; 106(3):349–356. [PubMed: 20089114]
- [45]. Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. *Cancer*. 2009; 115(13):2881–2890. [PubMed: 19399906]
- [46]. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. *J. Clin. Oncol*. 2007; 25(16):2218–2224. [PubMed: 17538166]
- [47]. Blehm KN, Spiess PE, Bondaruk JE, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. *Clin. Cancer Res*. 2006; 12(15):4671–4677. [PubMed: 16899617]
- [48]. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science*. 2004; 304(5676):1497–1500. [PubMed: 15118125]
- [49]. Gallucci M, Guadagni F, Marzano R, et al. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. *J. Clin. Pathol*. 2005; 58(4):367–371. [PubMed: 15790699]
- [50]. Gallucci M, Merola R, Leonardo C, et al. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. *BJU Int*. 2005; 96(3):440. author reply 440-1. [PubMed: 16042748]
- [51]. Desmedt C, Sperinde J, Piette F, et al. Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. *Diagn. Mol. Pathol*. 2009; 18(1):22–29. [PubMed: 19214112]
- [52]. McConkey DJ, Choi W, Marquis L, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. *Cancer Metastasis Rev*. 2009; 28(3-4):335–344. [PubMed: 20012924]

- [53]. Adam L, Zhong M, Choi W, et al. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. *Clin. Cancer Res.* 2009; 15(16):5060–5072. [PubMed: 19671845]
- [54]. Porta DG, Molle S, Stamm C, et al. TKI258, a multi-targeted receptor tyrosine kinase (RTK) inhibitor, is efficacious in preclinical models of bladder. cancer. 2008
- [55]. Metalli D, Lovat F, Tripodi F, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. *Am. J. Pathol.* 2010; 176(6):2997–3006. [PubMed: 20395438]
- [56]. McKian KP, Haluska P. Cixutumumab. *Expert Opin. Investig. Drugs.* 2009; 18(7):1025–1033.
- [57]. Levitt JM, Yamashita H, Jian W, et al. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. *Mol. Cancer. Ther.* 2010; 9(5):1128–1135. [PubMed: 20406945]
- [58]. Wu X, Obata T, Khan Q, et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. *BJU Int.* 2004; 93(1):143–150. [PubMed: 14678387]
- [59]. Hansel DE, Platt E, Orloff M, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. *Am. J. Pathol.* 2010; 176(6):3062–3072. [PubMed: 20395440]
- [60]. Milowsky MI, Trout A, Regazzi AM, et al. Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. *J. Clin. Oncol.* 2010; 28(15s)
- [61]. Shen SS, Smith CL, Hsieh JT, et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. *Cancer.* 2006; 106(12):2610–2616. [PubMed: 16700038]
- [62]. Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression. *Urol. Oncol.* 2009
- [63]. Teng J, Wang ZY, Jarrard DF, et al. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. *Endocr. Relat. Cancer.* 2008; 15(1):351–364. [PubMed: 18310301]
- [64]. Dellagrammaticas D, Bryden AA, Collins GN. Regression of metastatic transitional cell carcinoma in response to tamoxifen. *J. Urol.* 2001; 165(5):1631. [PubMed: 11342939]
- [65]. Sonpavde G, Okuno N, Weiss H, et al. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. *Urology.* 2007; 69(6):1221–1226. [PubMed: 17572228]
- [66]. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. *Clin. Cancer Res.* 2010; 16(10):2861–2871. [PubMed: 20460488]
- [67]. Honma I, Kitamura H, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. *Cancer Immunol. Immunother.* 2009; 58(11):1801–1807. [PubMed: 19294381]
- [68]. Bradley DA, Morse M, Keler T, et al. A randomized phase II study of a novel antigen-presenting cell-targeted hCG- β vaccine (the CDX-1307 regimen) in muscle-invasive bladder cancer. *J. Clin. Oncol.* 2010; 28(15s)
- [69]. Sonpavde G, Sternberg CN, Rosenberg JE, et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. *Lancet Oncol.* 2010; 11(9):861–870. [PubMed: 20537950]
- [70]. Theodore C, Bidault F, Bouvet-Forteau N, et al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. *Ann. Oncol.* 2006; 17(6):990–994. [PubMed: 16600984]
- [71]. Winquist E, Vokes E, Moore MJ, et al. A Phase II study of oxaliplatin in urothelial cancer. *Urol. Oncol.* 2005; 23(3):150–154. [PubMed: 15907713]
- [72]. Srinivas S, Harshman LC. A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. *Chemotherapy.* 2009; 55(5):321–326. [PubMed: 19641314]
- [73]. Boukovinas I, Androulakis N, Vamvakas L, et al. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II

study of the Hellenic Oncology Research Group. *Ann. Oncol.* 2006; 17(11):1687–1692. [PubMed: 16968872]

- [74]. Neri B, Vannini L, Giordano C, et al. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study. *Anticancer Drugs.* 2007; 18(10):1207–1211. [PubMed: 17893522]
- [75]. Dumez H, Martens M, Selleslach J, et al. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. *Anticancer Drugs.* 2007; 18(2):211–218. [PubMed: 17159607]
- [76]. Milowsky MI, Nanus DM, Maluf FC, et al. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. *J. Clin. Oncol.* 2009; 27(25):4062–4067. [PubMed: 19636012]
- [77]. Lin CC, Hsu CH, Huang CY, et al. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. *Anticancer Drugs.* 2007; 18(4):487–491. [PubMed: 17351402]
- [78]. Rosenberg JE, Halabi S, Sanford BL, et al. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. *Ann. Oncol.* 2008; 19(5):946–950. [PubMed: 18272914]
- [79]. Papageorgiou A, Kamat A, Benedict WF, et al. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. *Mol. Cancer. Ther.* 2006; 5(12):3032–3041. [PubMed: 17172406]
- [80]. Bonfil RD, Russo DM, Binda MM, et al. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. *Urol. Oncol.* 2002; 7(4):159–166. [PubMed: 12474532]
- [81]. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. *Br. J. Cancer.* 2006; 94(10):1395–1401. [PubMed: 16622447]
- [82]. Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. *Cancer.* 2009; 115(18):4110–4117. [PubMed: 19536904]
- [83]. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. *J. Clin. Oncol.* 2009; 27(27):4454–4461. [PubMed: 19687335]
- [84]. Hirata Y, Uemura D. Halichondrins- antitumor polyether macrolides from a marine sponge. *Pure & Appl. Chem.* 1986; 58(5):701–710.
- [85]. Quinn DI, Aparicio A, Tsao-Wei DD, et al. Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial. *J. Clin. Oncol.* 2010; 28(15s)
- [86]. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. *J. Clin. Oncol.* 2005; 23(31):7785–7793. [PubMed: 16258082]
- [87]. Sridhar, SS.; Canil, CM.; Mukherjee, SD., et al. A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma; Proceedings of the American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium; 2010;
- [88]. Reichenbach H, Hofle G. Discovery and development of the epothilones: a novel class of antineoplastic drugs. *Drugs R. D.* 2008; 9(1):1–10. [PubMed: 18095749]
- [89]. Dreicer R, Li S, Manola J, et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. *Cancer.* 2007; 110(4):759–763. [PubMed: 17594721]
- [90]. Hensley ML, Dizon D, Derosa F, et al. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. *Invest. New Drugs.* 2007; 25(4):335–341. [PubMed: 17364235]

- [91]. Dreicer R, Li H, Cooney MM, et al. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. *Cancer*. 2008; 112(12):2671–2675. [PubMed: 18459175]
- [92]. von der Maase H, Lehmann J, Gravis G, et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. *Ann. Oncol.* 2006; 17(10):1533–1538. [PubMed: 16873433]
- [93]. Galsky MD, Mironov S, Iasonos A, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. *Invest. New Drugs*. 2007; 25(3):265–270. [PubMed: 17146733]
- [94]. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. *J. Clin. Oncol.* 2006; 24(21):3451–3457. [PubMed: 16849761]
- [95]. Cheung EM, Quinn DI, Tsao-Wei DD, et al. Phase II study of vorinostat (Suberoylanilide Hydroxyamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy--California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial. *J. Clin. Oncol.* 2008; 26(May 20 suppl) abstr 16058.
- [96]. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. *Cancer Treat. Rev.* 2007; 33(1):9–23. [PubMed: 17084534] * Thorough review of mechanisms of platinum resistance and clinical utility of platinating agents.
- [97]. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. *J. Clin. Oncol.* 2006; 24(23):3799–3808. [PubMed: 16896009]
- [98]. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. *Clin. Cancer Res.* 2008; 14(5):1291–1295. [PubMed: 18316546] * Discussion of platinum resistance with an emphasis on the contributions of DNA repair pathways and translational implications.
- [99]. Welsh C, Day R, McGurk C, et al. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. *Int. J. Cancer*. 2004; 110(3):352–361. [PubMed: 15095299]
- [100]. Selvakumaran M, Pisarcik DA, Bao R, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. *Cancer Res.* 2003; 63(6):1311–1316. [PubMed: 12649192]
- [101]. Bellmunt J, Paz-Ares L, Cuella M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. *Ann. Oncol.* 2007; 18(3):522–528. [PubMed: 17229776] * Clinical trial that tested ERCC1 as a predictive biomarker of cisplatin sensitivity and provides an example of how such biomarker-driven studies may be designed.
- [102]. Guix M, Lema L, Lloreta J, et al. Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry. *ASCO Meeting Abstracts*. 2009; 27(15S):5025.
- [103]. Stojic L, Mojas N, Cejka P, et al. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. *Genes Dev.* 2004; 18(11):1331–1344. [PubMed: 15175264]
- [104]. van der Post RS, Kiemeny LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. *J. Med. Genet.* 2010; 47(7):464–470. [PubMed: 20591884]
- [105]. Saletta F, Matullo G, Manuguerra M, et al. Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. *Cancer Res.* 2007; 67(15):7088–7094. [PubMed: 17671175]
- [106]. Narter KF, Ergen A, Agachan B, et al. Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). *Anticancer Res.* 2009; 29(4):1389–1393. [PubMed: 19414392]
- [107]. Gao J, Huang HY, Pak J, et al. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. *Oncogene*. 2004; 23(3):687–696. [PubMed: 14737103]

- [108]. Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. *Mol. Cancer. Ther.* 2006; 5(5):1239–1247. [PubMed: 16731756]
- [109]. Stadler WM, Lerner SP, Groshen S, et al. Randomized trial of p53 targeted adjuvant therapy for patients (pts) with organ- confined node-negative urothelial bladder cancer (UBC). ASCO Meeting Abstracts. 2009; 27(15S):5017.
- [110]. Goebell PJ, Groshen SG, Schmitz-Drager BJ, et al. P53 Immunohistochemistry in Bladder Cancer--a New Approach to an Old Question. *Urol. Oncol.* 2010; 28(4):377–388. [PubMed: 20610276]
- [111]. Pagliaro LC, Keyhani A, Liu B, et al. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. *Urol. Oncol.* 2003; 21(6):456–462. [PubMed: 14693272]
- [112]. Miyake H, Yamanaka K, Muramaki M, et al. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. *Neoplasia.* 2005; 7(2):171–179. [PubMed: 15802022]
- [113]. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. *N. Engl. J. Med.* 2010; 362(20):1909–1919. [PubMed: 20484397]
- [114]. Shen X, Do H, Li Y, et al. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. *Mol. Cell.* 2009; 35(5):716–723. [PubMed: 19748364]
- [115]. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. *Clin. Cancer Res.* 2007; 13(24):7413–7420. [PubMed: 18094425]
- [116]. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. *Cancer Res.* 2003; 63(19):6221–6228. [PubMed: 14559807]
- [117]. Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. *PLoS One.* 2008; 3(11):e3695. [PubMed: 19002265]
- [118]. Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. *Ann. Oncol.* 2010
- [119]. Stordal B, Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. *Curr. Cancer. Drug Targets.* 2009; 9(3):354–365. [PubMed: 19442054]
- [120]. Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladder cancer. *Urol. Oncol.* 2010; 28(4):389–400. [PubMed: 20610277]
- [121]. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell.* 2009; 136(2):215–233. [PubMed: 19167326]
- [122]. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. *Annu. Rev. Biochem.* 2010; 79:351–379. [PubMed: 20533884]
- [123]. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. *Annu. Rev. Med.* 2009; 60:167–179. [PubMed: 19630570] ** Excellent introduction to role of microRNAs in cancer as oncogenes, tumor suppressors, and therapeutic targets
- [124]. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. *Nat. Biotechnol.* 2008; 26(4):462–469. [PubMed: 18362881]
- [125]. Hasemeier B, Christgen M, Kreipe H, et al. Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology. *BMC Biotechnol.* 2008; 8:90. [PubMed: 19038028]
- [126]. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. *Eur. J. Cancer.* 2010; 46(2):298–311. [PubMed: 19948396]
- [127]. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. *Mol. Cancer. Ther.* 2008; 7(7): 2152–2159. [PubMed: 18645025]

- [128]. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. *J. Biol. Chem.* 2008; 283(44):29897–29903. [PubMed: 18708351]
- [129]. Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. *Cancer Res.* 2008; 68(24):10307–10314. [PubMed: 19074899]
- [130]. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. *J. Clin. Oncol.* 2010; 28(16):2777–2783. [PubMed: 20406928]
- [131]. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. *Proc. Natl. Acad. Sci. U. S. A.* 2007; 104(32):13086–13091. [PubMed: 17666531]
- [132]. Lee JK, Coutant C, Kim YC, et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. *Clin. Cancer Res.* 2010; 16(2):711–718. [PubMed: 20068086] * Example of how gene expression profiling may be used to improve the prediction of chemosensitivity with potential applications for personalized therapy.
- [133]. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. *J. Clin. Oncol.* 2005; 23(9):2020–2027. [PubMed: 15774793]
- [134]. Krega S, Rexer H, vom Dorp F, et al. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). *ASCO Meeting Abstracts.* 2010; 28(15_suppl):4574.
- [135]. Bellmunt J, Maroto P, Mellado B, et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. *ASCO Meeting Abstracts.* 2008; 26(15_suppl):291.
- [136]. Beuzeboc P, Banu E, Voog G, et al. Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study. *J. Clin. Oncol.* 2007; 25(18S (June 20 Suppl))

Executive Summary

- Personalized medicine has brought significant improvements to the diagnosis and treatment of multiple cancers, but advances in urothelial carcinoma lag behind despite detailed understanding of the molecular pathways driving this disease.
- Platinum-based combination chemotherapy remains the standard, first-line treatment for advanced urothelial carcinoma and is also used for neoadjuvant and adjuvant chemotherapy for locally advanced disease.
- Recent clinical trial results of targeted therapies against urothelial cancers, such as angiogenesis inhibitors, and growth factor inhibitors have generally been disappointing.
- Novel chemotherapy agents currently or recently in testing include *Vinca* alkaloids, microtubule dynamics inhibitors, nanoparticle taxanes, epothilones, antifolates, and histone deacetylase inhibitors.
- Emerging data suggests that alterations in DNA repair pathways, specifically homologous recombination, nucleotide excision repair, and mismatch repair, may mediate resistance to platinum agents in urothelial carcinoma.
- The field of microRNAs represents a new tool in the search for novel biomarkers and may help to reveal mechanisms of cancer pathogenesis that can be exploited as therapeutic targets.

Keywords

- **Bacillus Calmette-Guerin** (BCG) is a vaccine prepared from live attenuated *Mycobacterium bovis* against tuberculosis.
- **Low-grade urothelial cancers** often have “gain-of-function” oncogene mutations.
- **High-grade urothelial cancers** are characterized by “loss-of-function” mutations in tumor suppressor genes.
- **Epithelial-to-mesenchymal transition** (EMT) is a process whereby cells lose the ability to adhere together and gain increased mobility.
- **Taxanes**, such as paclitaxel, are agents that prevent depolymerization of microtubules, which inhibits mitosis, and they also function as radiosensitizers.

Table 1

Summary of clinical trials of angiogenesis inhibitors

	Reference	Phase and Setting	Treatment	Response Rate	Median OS (months)	Median PFS (months)	Comments
Bevacizumab	Hahn [28]	Phase II 1 st line advanced UC	GC + Bev	CR: 9/43 pts (21%) PR: 22/43 (51%)	20.4	8.2	Grade 3-4 non-hematologic toxicity included: DVT/PE 21%, hemorrhage 7%, hypertension 5%, proteinuria 2%.
	NCT00942331 (www.clinicaltrials.gov)	Phase III 1 st or 2 nd advanced UC	GC +/- Bev				
	NCT00268450	Phase II neoadjuvant/adjuvant locally advanced UC	neoadjuvant GC + Bev, followed by adjuvant paclitaxel + Bev				
Aflibercept	NCT00588666	Phase II 1 st line advanced UC	Gemcitabine, Carboplatin + Bev				
	Twardowski [29]	Phase II 2 nd line advanced UC	single-agent aflibercept	PR: 1/22 (4.5%)	NA	2.79	Similar toxicity as other VEGF inhibitors: hypertension, proteinuria, hemorrhage.[29]
	Sridhar [32]	Phase II 1 st line advanced UC	single-agent sorafenib	OR: none SD >3mo: 1/17 (6%) SD <3mo: 3/17 (18%)	5.9	1.9	Most common 3+ toxicities: abdominal pain, back pain, hand/foot reaction, bladder infection.
	Dreicer [33]	Phase II 2 nd line advanced UC	single-agent sorafenib	OR: none	6.8	4-month PFS: 9.5%	Most common 3+ toxicities: fatigue, hand-foot reaction.
	Krege [134]	Phase II 1 st line advanced UC	GC +/- sorafenib	NA	NA	NA	42% received only 1-2 cycles of chemotherapy Similar toxicity between arms: 43% (placebo) vs 49% (sorafenib)
	NCT01222676	Phase II neoadjuvant locally advanced UC	GC + sorafenib				
	NCT00461851	Phase II 1 st line advanced UC	GC + sorafenib				

	Reference	Phase and Setting	Treatment	Response Rate	Median OS (months)	Median PFS (months)	Comments
	NCT00544609	Phase I 1 st line locally advanced UC	sorafenib with radiotherapy				
Sunitinib	Gallagher [30]	Phase II 2 nd line advanced UC	single-agent sunitinib, either 4 wk on/2 wk off (cohort A) or continuous dosing (cohort B)	PR cohort A: 3/45 pts (7%) PR cohort B: 1/32 (3%) PR + SD: 33/77 (43%)	7.1 vs 6.0 (A vs B)	2.4 vs 2.3 (A vs B)	Included 26% renal pelvis or ureter primary urothelial tumors 61% experienced grade 3-4 toxicity
	Galsky [31]	Phase II 1 st line advanced UC	GC + sunitinib (up to 6 cycles), followed by daily sunitinib until progression	PR: 8/15 pts (53%) SD: 1/15 (7%)	NA	NA	Significant toxicity: 40% discontinued tx <3 cycles. Neutropenia (80%), 1 septic death.
	Bradley [68]	Phase II maintenance advanced UC with CR/PR/SD following 4-6 cycles of CT	sunitinib vs placebo, 4wk on/2 wk off	SD × 24wk: 2/7 (29%) PR ×60wk: 1/7 (14%)	NA	2.2 (on open- label sunitinib)	No grade 4-5 adverse events.
	Bellmunt [135]	Phase II 1 st line advanced UC, ineligible for cisplatin	sunitinib, 4wk on/2wk off	PR: 2/16 (8%) SD ×>3mon: 8/16 (50%)	NA	5.9	
	NCT00847015	Phase II neoadjuvant locally advanced UC	GC + sunitinib				
	NCT00526656	Phase II neoadjuvant locally advanced UC	single-agent sunitinib				
	NCT01042795	Phase II adjuvant locally advanced UC	single-agent sunitinib following platinum- based neoadjuvant CT and cystectomy				
	NCT01089088	Phase II 1 st line unresectable locally advanced/advanced UC	GC + sunitinib				
	NCT01118039	Phase II 1 st line unresectable locally advanced/locally recurrent/advanced UC, ineligible for	single-agent sunitinib				

	Reference	Phase and Setting	Treatment	Response Rate	Median OS (months)	Median PFS (months)	Comments
		cisplatin					
	NCT00792025	Phase II 2 nd line locally advanced/ advanced UC	single-agent sunitinib				
	NCT01118351	Phase II recurrent non-muscle invasive UC	single-agent sunitinib				
Pazopanib	Necchi [34]	Phase II 2 nd line advanced UC	single-agent pazopanib	PR: 4/18 (22%) SD: 11/18 (61%)	NA	NA	Results after median follow-up of 3 months.
	NCT00471536	Phase II 2 nd line advanced UC	single-agent pazopanib				Recently completed; not yet reported.
	NCT01265940	Phase I/II 2 nd line advanced UC	vinflunine + pazopanib				
	NCT01108055	Phase II 2 nd line advanced UC	weekly paclitaxel + pazopanib				

Abbreviations: OS, overall survival; PFS, progression free survival; UC, urothelial carcinoma; GC, gemcitabine and cisplatin; Bev, bevacizumab; CR, complete response; PR, partial response; OR, objective response rate; SD, stable disease; pts, patients; DVT, deep venous thrombosis; PE, pulmonary embolus; NA, not available; wk, week; CT, chemotherapy; RT, radiation therapy.

Table 2

Summary of clinical trials of growth factor inhibitors

	Reference	Phase and Setting	Treatment	Response Rate	Median OS (months)	Median PFS (months)	Comments
Gefitinib (ZD1839)	Petrylak [42] (SWOG S0031)	Phase II 2 nd line advanced UC	single-agent ZD1839	PR: 1/31 pts (3%) SD: 2/31 (6.5%)	3	2	Felt to be ineffective as 2 nd agent for UC.
	Philips [43] (CALGB 90102)	Phase II 1 st line advanced UC	GC + gefitinib x6 cycles, followed by maintenance gefitinib for responding or SD	OR: 23/54 pts (42.6%)	15.1	7.4	No improvement in RR or OS compared to historical controls of GC.
Erlotinib	Pruthi [44]	Phase II neoadjuvant locally advanced UC	single-agent erlotinib	pT0 rate: 5/20 pts (25%) <pT1: 7/20 (35%) OCD: 15/20 (75%)	50% alive with NED at 24.8 months	NA	Most common AE was drug rash; all patients with pT0 or pTis/T1 had rash.
	NCT00749892	Phase II neoadjuvant locally advanced or recurrent UC	single-agent erlotinib				
	NCT00380029	Phase II neoadjuvant/maintenance locally advanced UC	neoadjuvant single-agent erlotinib, followed by maintenance erlotinib				
Cetuximab	NCT00645593	Phase II 1 st line advanced UC	GC +/- cetuximab				
Lapatinib	Wulfing [45]	Phase II 2 nd line advanced UC	single-agent lapatinib	OR > 10%: 1.7% pts SD: 18/59 (31%)	17.9	8.6	42% could not be evaluated for response. Clinical benefit correlated with EGFR overexpression.
	NCT01245660	Phase 0 neoadjuvant locally advanced UC	single-agent lapatinib				Primary endpoint is effect on EGFR pathway at molecular level.
	NCT00949455 (LaMB UK study)	Phase II/III maintenance advanced UC with Her1/2 overexpression	maintenance lapatinib vs placebo				
	NCT00623064	Phase I 1 st line	GC + lapatinib				

	Reference	Phase and Setting	Treatment	Response Rate	Median OS (months)	Median PFS (months)	Comments
Trastuzumab	Hussain [46]	advanced UC					
		Phase II 1 st line advanced UC with Her- 2/neu overexpression	paclitaxel, carboplatin, gemcitabine + trastuzumab	CR: 5/44 pts (11%) PR: 26/44 (59%)	14.1	9.3	Grade 1-3 cardiac toxicity in 22.7%.
	Beuzeboc [136]	Phase II 1 st line advanced UC with HER2 overexpression	gemcitabine, platinum CT +/- trastuzumab	NA	NA	NA	No serious cardiac AEs reported in either arm.
	NCT00238420	Phase I/II adjuvant locally advanced UC, ineligible for cystectomy	paclitaxel and RT +/- trastuzumab following transurethral surgery				
	NCT00004856	Phase II 2 nd line advanced UC	single-agent trastuzumab				
MGAH22	NCT01195935	Phase I 2 nd line HER2-positive tumors, including UC	single-agent MGAH22				MGAH22 is a novel anti-HER2 monoclonal antibody.
	NCT01148849	Phase I 2 nd line HER2-positive tumors, including UC	single-agent MGAH22				
TKI12458	NCT00790426	Phase II 2 nd and 3 rd line advanced UC	single-agent MGAH22				TKI12458 is a TKI against FGFR-3. FGFR-3 mutant and wild type tumors eligible.

Abbreviations: OS, overall survival; PFS, progression free survival; UC, urothelial carcinoma; GC, gemcitabine and cisplatin; Bev, bevacizumab; CR, complete response; PR, partial response; OR, objective response rate; SD, stable disease; pts, patients; DVT, deep venous thrombosis; PE, pulmonary embolus; NA, not available; RR, response rate; OCD, organ confined disease; AE, adverse event; RT, radiation therapy; HER2, human epidermal growth receptor 2; TKI, tyrosine kinase inhibitor; FGFR-3, fibroblast growth factor receptor-3.